Literature DB >> 8049494

Hypothalamic hormones: from neuroendocrinology to cancer therapy.

A V Schally1.   

Abstract

The discovery of hypothalamic hormones, especially LH-RH and somatostatin has led to practical clinical use of their analogs in the field of cancer treatment. Bombesin/GRP antagonists can be also considered for the development of new methods for treatment of various tumors. The understanding of functions of these peptide hormones and the availability of their synthetic analogs should permit the clinicians to treat a variety of cancers more successfully than in the past.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8049494

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN： 0959-4973            Impact factor:   2.248


  7 in total

1.  Preparation, characterization, and biodistribution study of technetium-99m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice.

Authors:  N Arulsudar; N Subramanian; P Mishra; K Chuttani; R K Sharma; R S R Murthy
Journal:  AAPS PharmSci       Date:  2004-02-06

2.  Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

Authors:  M Kovacs; A V Schally; A Nagy; M Koppan; K Groot
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

3.  Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.

Authors:  K Szepeshazi; A V Schally; G Halmos; B Szoke; K Groot; A Nagy
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

5.  Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.

Authors:  G Halmos; A V Schally; J Pinski; M Vadillo-Buenfil; K Groot
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

6.  Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.

Authors:  K Szepeshazi; A V Schally; K Groot; P Armatis; G Halmos; F Herbert; B Szende; J L Varga; M Zarandi
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

Review 7.  Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.

Authors:  Carsten Gründker; Günter Emons
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.